A review of Phase 2 and 3 clinical trial data on oral GLP-1 receptor agonists is now informing how clinicians think about positioning these agents relative to injectables in chronic weight management practice
Improved Cognitive Function: Some studies indicate that GLP-1 receptor agonists may help alleviate cognitive deficits associated with nicotine withdrawal, which often contribute to relapse
The analysis included 173,846 patients (86,923 per cohort) after propensity score matching for demographic, metabolic, and systemic covariates.The researchers found that compared with the lifestyle intervention alone cohort, tirzepatide use was associated with a reduced 12-month risk for DR incidence and worsening events, including incident mild nonproliferative DR, proliferative DR, DR with macular edema, vitreous hemorrhage, tractional retinal detachment, intravitreal antivascular endothelial growth factor injection, and pan-retinal photocoagulation (risk ratios, 0.864, 0.705, 0.624, 0.607, 0.370, 0.479, and 0.610, respectively)."Our study and others suggest that medications like semaglutide and tirzepatide may not affect diabetic retinopathy in the same way," Shah said in a statement
Q5: Where should I inject Obesema 0.5mg
Analysis of usage pattern of glutathione by dermatologists: Results of a cross-sectional study
Rapid weight loss caused by Ozempic and other GLP-1 medications may cause fat loss from the vulva and vagina
